VHL-Directed PROTAC Compounds for Androgen Receptor Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for prostate cancer and other conditions related to aberrant androgen receptor (AR) activity, such as Kennedy's Disease, face challenges due to resistance development and the need for effective therapies that target AR degradation.
Innovation Solution
Development of bifunctional compounds, known as PROTACs, which recruit AR proteins to E3 ubiquitin ligases like VHL, facilitating their ubiquitination and degradation through a linker moiety, thereby modulating AR activity and promoting targeted protein degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bifunctional PROTAC compounds are used to target AR degradation, then AR protein levels are reduced effectively, but the complexity of the treatment mechanism increases compared to traditional AR inhibition approaches
Solution Approach 1:
The PROTAC compound is segmented into three functional modules: an AR-binding moiety (ABM), a linker moiety (L), and a VHL E3 ligase-binding moiety (VLM). This segmentation allows each component to perform its specific function independently while working together to achieve AR degradation, resolving the contradiction by making the complex mechanism modular and manageable.
Solution Approach 2:
The linker moiety acts as an intermediary that physically connects the AR-binding moiety and the VHL E3 ligase-binding moiety. This intermediary structure enables the formation of a ternary complex between AR, PROTAC, and VHL E3 ligase, facilitating the degradation process while organizing the complexity into a structured intermediate state.
2Device complexity
If traditional AR inhibition methods are used, then the treatment approach is simple and well-established, but resistance development occurs limiting long-term effectiveness
Solution Approach 1:
Instead of inhibiting AR function (the traditional approach), the PROTAC compound inverts the strategy by promoting AR degradation. This fundamental inversion from functional inhibition to protein elimination overcomes resistance mechanisms that develop against inhibitors, as degradation bypasses the need for AR functional blockade.
Solution Approach 2:
The invention changes the key parameter from AR functional inhibition to AR protein level reduction. By shifting the therapeutic parameter from preventing AR activity to eliminating AR protein, the treatment achieves sustained effectiveness without the resistance issues that arise from functional inhibition approaches.
3Productivity
If AR function inhibition is used to treat prostate cancer, then tumor growth is suppressed initially, but disease progression occurs due to resistance development
Solution Approach 1:
The PROTAC compound performs preliminary action by degrading AR protein before resistance can develop. By eliminating the target protein upfront rather than attempting to inhibit its function, the treatment prevents the emergence of resistant clones that would otherwise develop during prolonged inhibitor exposure.
Solution Approach 2:
The PROTAC approach treats AR as a disposable target that is continuously degraded and replenished, rather than attempting to permanently inhibit a resilient protein. This strategy of continuous low-level degradation prevents resistance by keeping AR levels below the threshold needed for resistance development, analogous to using short-lived objects that are constantly replaced.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PROTAC compounds effectively degrade AR proteins, leading to therapeutic benefits in treating prostate cancer and Kennedy's Disease by inducing apoptosis, suppressing transcriptional activity, and causing prostate involution, as demonstrated in preclinical models.
Implementation Method 1
bifunctional compounds, which are useful for the modifying the ubiquitination and subsequent degradation of target polypeptides and proteins
Implementation Method 2
the target protein/polypeptide is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein
Data Source
AI summary
The present disclosure relates to bifunctional compounds, which find utility to degrade (and inhibit) Androgen Receptor. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds Androgen Receptor such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of Androgen Receptor.